These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11739371)

  • 1. A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.
    Wang J; Stuckey JA; Wishart MJ; Dixon JE
    J Biol Chem; 2002 Jan; 277(4):2377-80. PubMed ID: 11739371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.
    Fernández-Sánchez ME; Criado-García O; Heath KE; García-Fojeda B; Medraño-Fernández I; Gomez-Garre P; Sanz P; Serratosa JM; Rodríguez de Córdoba S
    Hum Mol Genet; 2003 Dec; 12(23):3161-71. PubMed ID: 14532330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease.
    Girard JM; Lê KH; Lederer F
    Biochimie; 2006 Dec; 88(12):1961-71. PubMed ID: 17010495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies.
    Ganesh S; Tsurutani N; Suzuki T; Hoshii Y; Ishihara T; Delgado-Escueta AV; Yamakawa K
    Biochem Biophys Res Commun; 2004 Jan; 313(4):1101-9. PubMed ID: 14706656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between glycogen accumulation and the laforin dual specificity phosphatase.
    Wang W; Parker GE; Skurat AV; Raben N; DePaoli-Roach AA; Roach PJ
    Biochem Biophys Res Commun; 2006 Nov; 350(3):588-92. PubMed ID: 17022935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain.
    Ganesh S; Tsurutani N; Suzuki T; Ueda K; Agarwala KL; Osada H; Delgado-Escueta AV; Yamakawa K
    Hum Mol Genet; 2003 Sep; 12(18):2359-68. PubMed ID: 12915448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo.
    Tagliabracci VS; Turnbull J; Wang W; Girard JM; Zhao X; Skurat AV; Delgado-Escueta AV; Minassian BA; Depaoli-Roach AA; Roach PJ
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19262-6. PubMed ID: 18040046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.
    Ganesh S; Agarwala KL; Ueda K; Akagi T; Shoda K; Usui T; Hashikawa T; Osada H; Delgado-Escueta AV; Yamakawa K
    Hum Mol Genet; 2000 Sep; 9(15):2251-61. PubMed ID: 11001928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes.
    Ianzano L; Zhang J; Chan EM; Zhao XC; Lohi H; Scherer SW; Minassian BA
    Hum Mutat; 2005 Oct; 26(4):397. PubMed ID: 16134145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy.
    Ianzano L; Young EJ; Zhao XC; Chan EM; Rodriguez MT; Torrado MV; Scherer SW; Minassian BA
    Hum Mutat; 2004 Feb; 23(2):170-176. PubMed ID: 14722920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
    Vernia S; Rubio T; Heredia M; Rodríguez de Córdoba S; Sanz P
    PLoS One; 2009 Jun; 4(6):e5907. PubMed ID: 19529779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
    Ganesh S; Delgado-Escueta AV; Suzuki T; Francheschetti S; Riggio C; Avanzini G; Rabinowicz A; Bohlega S; Bailey J; Alonso ME; Rasmussen A; Thomson AE; Ochoa A; Prado AJ; Medina MT; Yamakawa K
    Hum Mol Genet; 2002 May; 11(11):1263-71. PubMed ID: 12019207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
    Couarch P; Vernia S; Gourfinkel-An I; Lesca G; Gataullina S; Fedirko E; Trouillard O; Depienne C; Dulac O; Steschenko D; Leguern E; Sanz P; Baulac S
    J Mol Med (Berl); 2011 Sep; 89(9):915-25. PubMed ID: 21505799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
    Gómez-Garre P; Sanz Y; Rodríguez De Córdoba SR; Serratosa JM
    Eur J Hum Genet; 2000 Dec; 8(12):946-54. PubMed ID: 11175283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.
    Gayarre J; Duran-Trío L; Criado Garcia O; Aguado C; Juana-López L; Crespo I; Knecht E; Bovolenta P; Rodríguez de Córdoba S
    Brain; 2014 Mar; 137(Pt 3):806-18. PubMed ID: 24430976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates.
    Worby CA; Gentry MS; Dixon JE
    J Biol Chem; 2006 Oct; 281(41):30412-8. PubMed ID: 16901901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy.
    Dubey D; Ganesh S
    Hum Mol Genet; 2008 Oct; 17(19):3010-20. PubMed ID: 18617530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of a laforin nanobody inhibitor.
    Simmons ZR; Sharma S; Wayne J; Li S; Vander Kooi CW; Gentry MS
    Clin Biochem; 2021 Jul; 93():80-89. PubMed ID: 33831386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen metabolism in tissues from a mouse model of Lafora disease.
    Wang W; Lohi H; Skurat AV; DePaoli-Roach AA; Minassian BA; Roach PJ
    Arch Biochem Biophys; 2007 Jan; 457(2):264-9. PubMed ID: 17118331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in NHLRC1 cause progressive myoclonus epilepsy.
    Chan EM; Young EJ; Ianzano L; Munteanu I; Zhao X; Christopoulos CC; Avanzini G; Elia M; Ackerley CA; Jovic NJ; Bohlega S; Andermann E; Rouleau GA; Delgado-Escueta AV; Minassian BA; Scherer SW
    Nat Genet; 2003 Oct; 35(2):125-7. PubMed ID: 12958597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.